Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab

Figures & data

Table 1 Patient demographics prior to starting omalizumab

Patient	Age	Sex	Weight (kg)	Race*	Skin prick testing**	A. fumigatus IgG	Total IgE (IU/L)	Eosinophilia/ mm^3	Prebronchodilator FEV1 (L)	Radiology
1	44	F	80	AA	G, WD, R, DM, MLD, AF	Negative	4362	0.6	3.28	Fleeting infiltrates CXR
2	45	M	84.6	C	MLD, AF	Not done	1128	0.4	1.71	Ground glass opacities on CT scan
3	56	M	102	C	T, G, R, DM, R, D, CR, AF, MLD	Present	565	0.5	1.30	Fleeting infiltrates CXR
4	58	F	76.5	AA	T, G, WD, RW, DM, C, CR, MLD	Present	863	0.4	2.82	Fleeting infiltrates CXR

Notes:

* AA-African American, C-Caucasian;

** T = Eastern 6 tree mix, G = K-O-T grass mix, WD = 3 weed mix, RW = ragweed mix, DM = D. farinae, C = standardized cat, D = dog epithelia, CR = cockroach mix, MLD = mold mix 1, mold mix 2, and mold mix 3, AF = A. fumigatus. Skin prick testing was done with Greer Laboratories. NC extracts and multi-test 2 device (Lincoln Diagnostics, IL).

Figure 1 Average monthly systemic steroid use based on patient records 6 months prior to initiation of omalizumab, at 6 month point and at 12 months of therapy (P = 0.01).

Figure 2A ACT daytime symptom impairment scores at baseline, 6 months, and 12 months of treatment with omalizumab.

Figure 2B ACT nighttime scores at baseline, 6 months, and 12 months of treatment with omalizumab.

Figure 3 Prebronchodialator FEV₁ (L) values at baseline and at 12 months.

Figure 4 Eosinophil levels at baseline and 12 months of treatment (P = 0.06).

Figure 5 Total serum IgE from baseline to 12 months of treatment with omalizumab (P = 0.4).